Health-related quality of life in patients with advanced colorectal cancer: Results from a phase II study of S-1 combined with irinotecan (CPT-11)

International Journal of Clinical Oncology

Volumn 15, Issue 3, 2010, Pages 280-286

  Tsunoda, Akira ^a,b   Yasuda, Naokuni ^c   Nakao, Kentaro ^d   Narita, Kazuhiro ^b   Watanabe, Makoto ^b   Matsui, Nobuaki ^b   Tsunoda, Yuko ^b   Kusano, Mitsuo ^b  

^a KAMEDA MEDICAL CENTER   (Japan)

^b SHOWA UNIVERSITY   (Japan)

^c Isezaki Municipal Hospital   (Japan)

^d Yamanashi Red Cross Hospital   (Japan)

Author keywords

Chemotherapy; Colorectal cancer; Health related quality of life; Irinotecan; Phase II study; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; IRINOTECAN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CAMPTOTHECIN; DRUG COMBINATION; OTERACIL; S 1 (COMBINATION); TEGAFUR;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BODY IMAGE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DETERIORATION; DIARRHEA; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERBILIRUBINEMIA; LEUKOPENIA; LONGITUDINAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PAIN ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RASH; SIDE EFFECT; SOCIAL STATUS; STOMATITIS; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT REDUCTION; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; COLORECTAL NEOPLASMS; DRUG COMBINATION; MIDDLE AGED; MORTALITY; PATHOLOGY; PSYCHOLOGY; TIME; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DRUG COMBINATIONS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OXONIC ACID; QUALITY OF LIFE; QUESTIONNAIRES; TEGAFUR; TIME FACTORS; TREATMENT OUTCOME;

EID: 77955714474     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-010-0059-4     Document Type: Article

References (31)

1. Saltz LB, Cox JV, Blanke C et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905-914
2. Douillard JY, Cunningham D, Roth AD et al (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355:1041-1047
3. Tournigand C, Andre T, Achille E et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229-237
4. Colucci G, Gebbia V, Paoletti G et al (2005) Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 23:4866-4875
5. Kohne CH, van Cutsem E, Wils J et al (2005) Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 23:4856-4865
6. Meta-analysis Group in Cancer (1998) Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16:301-308
7. Shirasaka T, Shimamato Y, Ohshimo H et al (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7:548-557
8. Ohtsu A, Baba H, Sakata Y et al (2000) Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group. Br J Cancer 83:141-145
9. Shirao K, Ohtsu A, Takada H et al (2004) Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma. Cancer 100:2355-2361
10. Tsunoda A, Yasuda N, Nakao K et al (2007) Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer. Oncology 72:58-63
11. Tsunoda A, Yasuda N, Nakao K et al (2009) Phase II study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer. Oncology 77:192-196
12. American Society of Clinical Oncology (1996) Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 14:671-679
13. de Kort SJ, Willemse PHB, Habraken JM et al (2006) Quality of life versus prolongation of life in patients treated with chemotherapy in advanced colorectal cancer: a review of randomized clinical trials. Eur J Cancer 42:835-845
14. Santana MJ, Au HJ, Dharma-Wardene M et al (2009) Healthrelated quality of life measures in routine clinical care: can FACT-fatigue help to assess the management of fatigue in cancer patients? Int J Technol Assess Health Care 25:90-96
15. Wang XS, Cleeland CS, Mendoza TR et al (1999) The effects of pain severity on health-related quality of life: a study of Chinese cancer patients. Cancer 86:1848-1855
16. Gupta D, Lis CG, Granick J et al (2006) Malnutrition was associated with poor quality of life in colorectal cancer: a retrospective analysis. J Clin Epidemiol 59:704-709
17. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216 (Pubitemid 30099779)
18. Aaronson NK, Ahmedzai S, Bergman B et al (1993) European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376
19. Sprangers MA, te Velde A, Aaronson NK (1999) The construction and testing of the EORTC colorectal cancer-specific quality of life questionnaire module (QLQ-CR38). Eur J Cancer 35:238-247
20. Kobayashi K, Takeda F, Teramukai S et al (1998) A cross-validation of the European Organization for Research and Treatment of Cancer QLQ-C30 (EORTC QLQ-C30) for Japanese with lung cancer. Eur J Cancer 34:810-815
21. Tsunoda A, Yasuda N, Nakao K et al (2008) Validation of the Japanese version of EORTC QLQ-CR38. Qual Life Res 17:317-322
22. EORTC Study Group on Quality of Life (1995) EORTC QLQC30 scoring manual. EORTC, Brussels
23. Fairclough DL (2004) Patient reported outcomes as endpoints in medical research. Stat Methods Med Res 12:115-138
24. Osoba D, Rodrigues G, Myles J et al (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139-144
25. King MT (1996) The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res 5:555-567
26. Osoba D, Tannock IF, Ernst SD et al (1999) Health-related quality of life in men with metastatic prostate cancer treated with prednisolone. J Clin Oncol 17:1654-1663
27. Blazeby JM, Avery K, Sprangers M et al (2006) Health-related quality of life measurements in randomized clinical trials in surgical oncology. J Clin Oncol 24:3178-3186
28. Cella D, Paul D, Yount S et al (2003) What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). Cancer Invest 21:526-535
29. Yuki S, Komatsu Y, Iwanaga I et al (2008) Phase II study of combination with irinotecan and S-1 (IRIS) for inoperable recurrent advanced colorectal cancer (HGCSG0302). Final analysis. Proc Am Soc Clin Oncol 26:20s (abstr. 15112)
30. Goto A, Yamada Y, Yasui H et al (2006) Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer. Ann Oncol 17:968-973
31. de Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947